Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease.

2021 ◽  
Author(s):  
Yutaro Ogawa ◽  
Takashi Nakahara ◽  
Masafumi Ono ◽  
Takumi Kawaguchi ◽  
Hiroshi Isoda ◽  
...  
Keyword(s):  
Liver Disease ◽  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Chronic Liver Disease ◽  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Chronic Liver ◽  
Continuous Glucose Monitoring System

scholarly journals Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system

2010 ◽  
Vol 162 (4) ◽  
pp. 705-710 ◽  
Author(s):  
Riccardo Schiaffini ◽  
Claudia Brufani ◽  
Beatrice Russo ◽  
Danilo Fintini ◽  
Antonella Migliaccio ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Glucose Metabolism ◽  
Glucose Tolerance ◽  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Glucose Monitoring ◽  
Continuous Glucose Monitoring System ◽  
Abnormal Glucose Tolerance ◽  
Altered Glucose

A long pre-diabetic phase of abnormal glucose tolerance is described in subjects with cystic fibrosis (CF) since childhood.ObjectiveThe aims of the study were to compare oral glucose tolerance test (OGTT) and continuous glucose monitoring system (CGMS) in the diagnosis of altered glucose metabolism, and to longitudinally evaluate the role of CGMS in predicting glucose metabolism deterioration in children with CF.MethodsSeventeen children with CF and 14 controls were enrolled (mean age 13.3±3.0 years). All subjects underwent OGTT and CGMS registration. On the basis of OGTT, children were classified as normal glucose tolerance, impaired glucose tolerance (IGT), IGT plus at least one glucose value above 200 mg/dl at intermediate OGTT points (IGT+200) and CF-related diabetes (CFRD). HbA1c, glucose area under the curve, insulin sensitivity, and insulinogenic and disposition indexes were also considered. Subjects with CF underwent another OGTT after 2.5 years.ResultsBaseline OGTT revealed 3/17 (7.6%) children with CF with at least one glucose value above 200 mg/dl (1 CFRD and 2 IGT+200), while CGMS revealed 6/17 (35.3%) children with glucose excursions above 200 mg/dl (P=0.010). None of the controls showed glucose over 200 mg/dl either at OGTT or at CGMS. At the 2.5-year follow-up OGTT, all the six subjects who had diabetic glucose excursion (i.e. >200 mg/dl) at baseline CGMS presented IGT+200 or CFRD. In logistic regression analysis, CGMS diabetic excursion was the strongest predictor of IGT+200 and CFRD (P<0.001).ConclusionsCGMS could be a useful tool to predict glucose metabolism derangements in children affected by CF.

scholarly journals Continuous Glucose Monitoring System in Acromegalic Patients: Possible Role in the Assessment of Glycemia Control

2020 ◽  
pp. 193229682094988
Author(s):  
Valeria Mercuri ◽  
Tania D’Amico ◽  
Denise Costa ◽  
Corrado De Vito ◽  
Luca D’Angelo ◽  
...  
Keyword(s):  
Glucose Tolerance ◽  
Monitoring System ◽  
Continuous Glucose Monitoring ◽  
Somatostatin Analogs ◽  
Glucose Monitoring ◽  
Tolerance Test ◽  
Continuous Glucose Monitoring System ◽  
Oral Glucose ◽  
Time Curve ◽  
Significant Difference

Background: Acromegaly is characterized by an insulin resistance condition. There is a significant difference between the different types of therapy in relation to the glycometabolic framework. The blinded continuous glucose monitoring system (CGMS), throughout a period of maximum 6 days for a total of 288 glycemic registrations per day, identifies glycemic excursions and could constitute a valid device to understand the 24-hour glycemic profiles. Aim of the study: To compare the oral glucose tolerance test (OGTT) and CGMS methods in acromegalic patients to evaluate their glycemic profiles, in relation to different treatments for acromegaly. Methods: Thirty-five acromegalic patients were divided into 18 somatostatin analogs (SSA), 9 pegvisomant, and 8 successfully surgically treated. A 72-hour CGM was performed and, immediately after, an OGTT. Results: Results obtained from OGTT: 11/35 impaired fasting glucose, 6/35 impaired glucose tolerance, and 4/35 diabetes mellitus. A positive significant correlation was demonstrated between the OGTT peak and CGM peak in all of the patients, CGM peak of patients treated with SSA and those surgically treated, OGTT average and CGM area under concentration–time curve (AUC) for hyperglycemia of patients treated with SSA and those surgically treated, and CGM AUC for hyperglycemia of patients treated with SSA and those surgically treated. Conclusions: Our results show a significantly higher response in terms of mean and peak OGTT in patients treated with SSA, both compared to the CGM study, and compared to the group of patients receiving pegvisomant. The CGM system could represent an instrument for the evaluation of the glycemic trend of acromegalic patients.

Role of Flash Glucose Monitoring System in Diabetic Patients with Chronic Liver Disease

2021 ◽  
Vol 15 (8) ◽  
pp. 2096-2099
Author(s):  
Sadiq Hussain Malik ◽  
Sara Reza ◽  
Farheen Aslam ◽  
Saleha Zafar ◽  
Sadaf Shafiq
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Monitoring System ◽  
Glucose Monitoring ◽  
Chronic Liver ◽  
Diabetic Patients ◽  
Flash Glucose Monitoring ◽  
Glucose Levels ◽  
Freestyle Libre ◽  
Flash Glucose Monitoring System

Background: Diabetic patients show serious complications of chronic liver disease. The monitoring of glucose in diabetic patients with chronic liver disease is very challenging. Generally, the glycaemic control monitoring in chronic liver disease patients is the same as in a person who does not have any liver disease. Flash glucose monitoring system is a way to measure glucose levels of body without pricking the body. It is an innovative method of measuring glucose levels. A flash glucose monitor is a small sensor. This sensor is a small sticky chip and is attached on the skin of the arm. One side of the chip has a small needle that goes inside the skin. It records glucose levels throughout day and night continuously. Levels of glucose can be assessed whenever wanted. Materials and Methods: The study was conducted in the Medical Ward 1, Bahawal Victoria Hospital, Bahawalpur and the Department of Pathology, Quaid-e-Azam Medical College, Bahawalpur from 1st January 2018 to June 2020. Freestyle Libre Sensor flash glucose monitoring system (by CoolPlus Medical) was used to measure glucose of subcutaneous interstitial fluid. The disposable sensor was applied to the back of the arm for up to 14 days. Sensor is calibrated by the factory with no automatic alarms. Results: We noticed that the results of the patients who had co-existing disease of chronic hepatitis and diabetes mellitus had same results of glucose readings when measured by flash glucose monitoring system and by finger prick for glucose measurement by glucometer. Conclusion: Flash glucose monitoring system is way better than self monitoring blood glucose method by glucometer in diabetic patients with chronic liver disease. Keywords: Diabetes, glucose, monitoring, chronic liver disease, complications

Sign in / Sign up

Export Citation Format

Share Document